NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Cut to $10.00 by Analysts at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target dropped by research analysts at BTIG Research from $25.00 to $10.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 178.94% from the company’s current price.

A number of other brokerages have also recently issued reports on NRXP. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Ascendiant Capital Markets increased their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Price Performance

NRXP stock traded up $0.49 during trading on Friday, hitting $3.58. 4,609,494 shares of the stock traded hands, compared to its average volume of 1,139,122. The stock has a market cap of $129.88 million, a price-to-earnings ratio of -3.28 and a beta of 2.18. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The firm’s 50 day moving average is $3.91 and its two-hundred day moving average is $2.91.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $19.43 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of large investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC grew its position in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter valued at approximately $107,000. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the period. State Street Corp lifted its stake in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Bleakley Financial Group LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $318,000. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.